Midazolam

8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine

Versed, Hypnovel, Dormicum

Psychoactive Class

Depressant Anxiolytic GABAergic Muscle Relaxant

Chemical Class

Midazolam is a short-acting depressant of the benzodiazepine class, specifically an imidazobenzodiazepine.¹² Patented in 1974 and adopted for medical use in 1982, it is distinguished from other benzodiazepines by its rapid onset and brief duration of action.¹² It is widely used clinically for procedural sedation, anesthesia, seizure management, and acute agitation,³⁴ and is included on the World Health Organization's List of Essential Medicines.⁵ Like all benzodiazepines, it carries a risk of dependence with repeated use.³

Dosage & Duration

Dosage

Threshold~1 mg

Light2.5-5 mg

Moderate5-15 mg

Strong15-30 mg

Heavy30+ mg

Bioavailability

~36%

Duration

Onset30-60 minutes

Come Up30-60 minutes

Peak1-2 hours

Offset1-2 hours

After Effects1-12 hours

Total2-4 hours

Half-life

2.2-6.8 hours

Subjective Effects

The midazolam experience is dominated by rapid, heavy sedation accompanied by pronounced anxiety relief, muscle relaxation, and dense anterograde amnesia. Onset is notably fast for a benzodiazepine, with sedation reaching its peak within minutes of intravenous administration and within roughly half an hour to an hour when given intramuscularly, frequently culminating in sleep. Rather than producing sensory alteration, the experience is one of overall dampening: feelings and perceptions are blunted, thought becomes clouded, and memory of the period after administration is often partially or entirely absent.

Physical

The body feels calm, heavy, and deeply relaxed, with loosened muscles, impaired coordination, and a strong pull toward sleep. At excessive doses this progresses to dangerously suppressed breathing, unresponsiveness, and low blood pressure.

Sedation

Heavy sedation with a fast onset is the dominant physical effect, typically ending in sleep.

Uncomfortable

Dizziness Headaches

Cognitive

The headspace is calm, blunted, and heavily anxiolytic, with markedly impaired memory formation. Confusion can emerge at higher doses, and paradoxical reactions involving restlessness, aggression, or outbursts of anger occur in a minority of users.

Disturbances

Suppressions

Cognitive suppression is the defining feature of the headspace, centered on anxiety relief, emotional blunting, and profound memory impairment.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Midazolam acts as a positive allosteric modulator at GABA-A receptors, binding at the benzodiazepine site.⁶ Rather than activating these receptors directly, it enhances the inhibitory effect of endogenous GABA by increasing the frequency of chloride ion channel opening, resulting in enhanced neural inhibition.⁴

Pharmacokinetics

Midazolam undergoes biotransformation primarily via CYP3A4, which is present in both the liver and gastrointestinal tract mucosa.⁷ This dual-site metabolism results in substantial first-pass metabolism and relatively low oral bioavailability.⁶ The major metabolic product is alpha-hydroxymidazolam, accounting for 60 to 70% of biotransformation products.⁷ This metabolite is at least as potent as the parent compound at benzodiazepine receptors, though it contributes only approximately 10% of overall biological activity. A minor metabolite, 4-hydroxymidazolam, accounts for 5% or less of metabolic output.⁷ Midazolam also undergoes glucuronide conjugation.⁷ Elimination half-life in adults is generally short, though it is prolonged in the elderly, young children, and adolescents.⁷ Renal and hepatic function also affect pharmacokinetic parameters.⁷

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholGHB/GBLOpioidsTramadol

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

DiphenhydraminePCP

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

DXMKetamineMXE

TripSit

Tolerance

Full Tolerance

Tolerance develops rapidly with continuous use. In intensive care settings, midazolam infusions may induce tolerance in a matter of days. With therapeutic use, benzodiazepine dependence occurs in approximately one-third of individuals treated for longer than 4 weeks.

Cross Tolerance

Benzodiazepines, GABAergic depressants

Harm Potential

Addiction & Dependence

Psychological

High

High psychological dependence potential with risk increasing with dose and duration of treatment.⁸ Risk factors include dependent personality, use of short-acting and high-potency benzodiazepines, and history of substance abuse.⁸

Physical

Extremely High

Physical dependence occurs in approximately one-third of individuals treated with benzodiazepines for longer than 4 weeks.⁴⁹ Midazolam infusions may induce tolerance and withdrawal syndrome in a matter of days.¹⁰ Sudden discontinuation can be dangerous or life-threatening, with withdrawal symptoms ranging from insomnia and anxiety to seizures and psychosis.¹¹ Gradual tapering is essential to minimize withdrawal and rebound effects.⁴

Toxicity

Central Nervous System

Long-term use of benzodiazepines has been associated with long-lasting deficits in memory, showing only partial recovery six months after cessation; it remains unclear whether full recovery occurs after longer periods of abstinence.¹²

Respiratory System

Respiratory depression is a known effect at typical doses, with serious respiratory adverse reactions including hypoventilation, airway obstruction, and apnea reported primarily at higher doses, in combination with other CNS depressants, or in vulnerable populations.¹¹

Cardiovascular

Hypotension due to reduction in systemic vascular resistance and increased heart rate can occur, particularly with rapid intravenous administration; serious cardiac adverse reactions have been reported in clinical settings.¹¹

Psychosis Risk

Psychosis may occur as a withdrawal symptom, particularly with abrupt discontinuation after prolonged use.¹¹ Paradoxical reactions including anxiety, aggressive or violent behavior, and uncontrollable emotional responses can occur in rare susceptible individuals, particularly in children, elderly, those with history of alcohol use or aggressive behavior, and with intravenous administration.⁴¹¹

Seizure Risk

While midazolam itself has anticonvulsant properties, withdrawal from benzodiazepines can cause seizures that may be life-threatening.⁴¹³ Paradoxical worsening of seizures occasionally occurs, and some benzodiazepines may trigger seizures in individuals with epilepsy. Gradual dose reduction is essential to prevent withdrawal seizures in dependent individuals.¹³

History & Culture

Discovery and Synthesis

Midazolam was synthesized in 1975 by Walser and Fryer at Hoffmann-LaRoche, Inc. in the United States.¹⁴ The compound was patented in 1974 and came into medical use in 1982. Its water solubility distinguished it from earlier benzodiazepines, as this property made it…

Legality

By Country

United StatesSchedule IV

Controlled under the Controlled Substances Act as a Schedule IV substance, indicating low potential for abuse and low risk of dependence relative to Schedule III substances.²⁶ DEA registration number 2884.²⁶ First approved by the FDA in 1985¹³ and remains available by prescription for various medical indications including procedural sedation, anesthesia induction, and seizure treatment.²⁷¹³

SwedenPrescription only

Regulated as a prescription-only medication.²⁵ Dispensing requires valid medical authorization from a licensed prescriber.

BrazilPrescription only

Available only with a valid medical prescription. Subject to pharmaceutical dispensing regulations requiring prescriber authorization.²⁴

References

Source Pages

Citations

Automated synthesis
Information aggregated and synthesized using an autonomous workflow built by Josie Kins.

Suggest an edit